Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis.
Front Pharmacol
; 14: 1303694, 2023.
Article
in En
| MEDLINE
| ID: mdl-38044937
Full text:
1
Database:
MEDLINE
Type of study:
Systematic_reviews
Language:
En
Journal:
Front Pharmacol
Year:
2023
Type:
Article
Affiliation country:
China